WO2023078813 - HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS
National phase entry:
Publication Number
WO/2023/078813
Publication Date
11.05.2023
International Application No.
PCT/EP2022/080318
International Filing Date
31.10.2022
Title **
[English]
HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS
[French]
MOLÉCULES HÉTÉROBIFONCTIONNELS UTILISÉES EN TANT QU'INHIBITEURS DE TEAD
Applicants **
MERCK PATENT GMBH
Frankfurter Strasse 250
64293 Darmstadt, DE
Inventors
HEINRICH, Timo
c/o Merck Healthcare KGaA
Frankfurter Strasse 250
64293 DARMSTADT, DE
GEHRTZ, Paul
c/o Merck Healthcare KGaA
Frankfurter Strasse 250
64293 DARMSTADT, DE
Priority Data
21205991.9
02.11.2021
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 4221 | |
| EPO | Filing, Examination | 15344 | |
| Japan | Filing | 589 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 11010 |
Total: 31739 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
have the meanings indicated in Claim 1, degrade target proteins, and can be employed, inter alia, for the treatment of diseases and conditions mediated by such target proteins.[French]
ont les significations indiquées dans la revendication 1, dégradent les protéines cibles, et peuvent être utilisés, entre autres, pour le traitement de maladies et d'états à médiation par de telles protéines cibles.